Document Detail


Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor.
MedLine Citation:
PMID:  8723394     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin II may contribute to the altered structure and function of small arteries. We proposed that angiotensin I-converting enzyme (ACE) inhibitor treatment could induce a regression of vascular remodeling. A double-blind trial was performed comparing effects of the ACE inhibitor cilazapril with the beta-blocker atenolol on small arteries obtained from biopsy specimens of subcutaneous gluteal fat. Nine patients with essential hypertension were randomized to cilazapril and eight to atenolol. Blood pressure was below 140/95 mm Hg under treatment for the duration of the study in all patients. Media-to-lumen ratio of small arteries of the patients, which before treatment was significantly higher than in normotensive subjects, was corrected after 1 year of treatment in the cilazapril group. There was no change in the increased media-to-lumen ratio of small arteries in the atenolol group, even after 2 years of treatment. Attenuated constrictor responses to endothelin-1 returned to normal only in the patients treated with cilazapril. Endothelium-dependent relaxation responses to acetylcholine were slightly depressed in hypertensive patients and improved in the cilazapril-treated group, but remained blunted in the arteries of the atenolol-treated patients. Treatment with cilazapril corrects small artery remodeling and endothelium-related functional abnormalities of gluteal subcutaneous small arteries in hypertensive patients. It remains to be demonstrated whether these apparently beneficial effects translate into reduced morbidity and mortality in hypertension.
Authors:
E L Schiffrin
Related Documents :
3910774 - Treatment of essential hypertension with captopril in patients with chronic obstructive...
12410854 - Renal damage associated with proteinuria.
22458744 - Sex differences in the endothelial function of untreated hypertension.
9409594 - Prospective characterization and selective management of the abdominal compartment synd...
9747964 - Reproducibility of erythrocyte sodium-lithium countertransport activity and ambulatory ...
14738644 - Measurement of trocar insertion force using a piezoelectric transducer.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  27 Suppl 2     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1996  
Date Detail:
Created Date:  1996-10-24     Completed Date:  1996-10-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S13-8     Citation Subset:  IM    
Affiliation:
MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Adult
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Arteries / drug effects,  pathology*,  physiopathology
Atenolol / therapeutic use
Blood Pressure / drug effects
Cilazapril / therapeutic use*
Endothelins / metabolism
Female
Humans
Hypertension / drug therapy*,  pathology*,  physiopathology
Male
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Endothelins; 29122-68-7/Atenolol; 92077-78-6/Cilazapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Importance of endothelial function in chronic heart failure.
Next Document:  Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure.